Mertansine (CAS 139504-50-0)
See product citations (1)
QUICK LINKS
Mertansine is a compound of interest in the field of chemical biology, primarily for its application in the study of cytotoxic agents. In research, mertansine is explored for its mechanism of action, which involves the inhibition of microtubule assembly, leading to cell cycle arrest and apoptosis in rapidly dividing cells. It is frequently conjugated to antibodies to form antibody-drug conjugates (ADCs), which are designed to deliver the cytotoxic agent specifically to target cells. In the context of materials science, mertansine may also be examined for its stability, conjugation chemistry, and the kinetics of its release from carriers. Additionally, researchers use mertansine to understand the structure-activity relationships of tubulin inhibitors, providing insights into the molecular basis of their binding affinity and specificity.
Mertansine (CAS 139504-50-0) References
- Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | Dillon, RL., et al. 2016. J Immunother. 39: 117-26. PMID: 26938945
- Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. | Wang, H., et al. 2017. Cancer Sci. 108: 1458-1468. PMID: 28388007
- Apoferritin nanocages loading mertansine enable effective eradiation of cancer stem-like cells in vitro. | Tan, T., et al. 2018. Int J Pharm. 553: 201-209. PMID: 30339945
- Bioinspired lipoproteins-mediated photothermia remodels tumor stroma to improve cancer cell accessibility of second nanoparticles. | Tan, T., et al. 2019. Nat Commun. 10: 3322. PMID: 31346166
- Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer. | Pandya, AD., et al. 2020. Biomacromolecules. 21: 1489-1498. PMID: 32092254
- Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes. | Choi, WG., et al. 2020. Pharmaceutics. 12: PMID: 32131538
- Targeting peptide-decorated biomimetic lipoproteins improve deep penetration and cancer cells accessibility in solid tumor. | Tan, T., et al. 2020. Acta Pharm Sin B. 10: 529-545. PMID: 32140397
- UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads. | Pysz, I., et al. 2020. J Chromatogr B Analyt Technol Biomed Life Sci. 1146: 122075. PMID: 32361467
- Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. | Huang, CT., et al. 2020. Mol Pharm. 17: 3392-3402. PMID: 32803984
- Tissue biodistribution and tumor targeting of near-infrared labelled anti-CD38 antibody-drug conjugate in preclinical multiple myeloma. | Cho, N., et al. 2021. Oncotarget. 12: 2039-2050. PMID: 34611478
- A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer. | Haji Ghaffari, M., et al. 2022. Breast Cancer. 29: 1121-1132. PMID: 35982394
- Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload. | Perrins, RD., et al. 2022. Nanomaterials (Basel). 12: PMID: 36432299
- Determination of Mertansine in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Pharmacokinetics of Mertansine in Rats | Choi, Won-Gu; Kim, Ju-Hyun; Jang, Hyun-Joon; Lee, Hye Suk. 2020. Mass Spectrometry Letters. Volume 11 Issue 3: 59-64.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mertansine, 2.5 mg | sc-482549 | 2.5 mg | $245.00 | |||
Mertansine, 10 mg | sc-482549A | 10 mg | $401.00 | |||
Mertansine, 50 mg | sc-482549B | 50 mg | $1170.00 | |||
Mertansine, 100 mg | sc-482549C | 100 mg | $2177.00 | |||
Mertansine, 1 g | sc-482549D | 1 g | $6591.00 |